Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407084 | 0.94 | ALDH1A1 (0.41) | ALDH1A1LMNAHSD11B1SLC9A1TSHR | |
| SCHEMBL4409273 | 0.92 | ALDH1A1 (0.40) | ALDH1A1LMNASLC9A1TSHR | |
| SCHEMBL20963387 | 0.92 | ALDH1A1 (0.40) | ALDH1A1LMNASLC9A1TSHR | |
| SCHEMBL4405692 | 0.86 | — | — | |
| SCHEMBL4672679 | 0.86 | ALDH1A1 (0.46) | ALDH1A1LMNAKMT2AHTR1AHTR2C | |
| SCHEMBL4409185 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNAMEN1KMT2AHTR1A | |
| SCHEMBL6474091 | 0.81 | ALDH1A1 (0.36) | ALDH1A1LMNASLC9A1HTR1AHTR2C | |
| SCHEMBL18723130 | 0.80 | LMNA (0.34) | ALDH1A1LMNATSHR | |
| SCHEMBL4406557 | 0.79 | KMT2A (0.42) | ALDH1A1LMNAMEN1KMT2ASLC9A1 | |
| SCHEMBL4407174 | 0.79 | ALDH1A1 (0.41) | ALDH1A1LMNAMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914234-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-3453707-B1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| EP-3453707-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2019-03-13 | — | — | EP | disclosed |
| WO-2018130838-A1 | THIOBENZOIMIDAZOLE AS FUNGICIDES | REDAG CROP PROTECTION LTD (GB) | 2018-07-19 | — | — | WO | disclosed |
| US-9616099-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARM INC (US) | 2016-05-19 | — | — | US | disclosed |
| US-9221878-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | ALDH1A1 3792/4885MAOB 3582/4885LMNA 4263/4885 |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | ALDH1A1 3792/4885MAOB 3582/4885LMNA 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.